SHERIDAN, WYOMING - April 12, 2026 - ABK Biomedical has completed enrollment of all 120 patients in ROUTE90, its pivotal U.S. FDA Investigational Device Exemption study evaluating Eye90 microspheres® for unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The milestone positions the Halifax-based medical device company to finalize one-year patient follow-up, then submit a Premarket Approval (PMA) application to the FDA. Eye90 microspheres hold FDA Breakthrough Device Designation, signaling regulatory recognition of the device's potential to address an unmet clinical need in liver cancer care.
What ROUTE90 measures and how it was designed
ROUTE90 is an international, prospective, Phase III, open-label, multi-center study registered on ClinicalTrials.gov (NCT05953337). The trial enrolled 120 patients across multiple sites and tracks two co-primary endpoints: confirmed Overall Response Rate and Duration of Response. Each enrolled patient is followed for one year post-treatment, meaning final data collection will precede the PMA filing.
Ammar Sarwar, MD, Professor of Radiology and Chief of Interventional Radiology at UPMC, and Andrew S. Kennedy, MD, Physician-in-Chief of HCA Healthcare's Sarah Cannon Cancer Network, served as co-principal investigators. Kennedy described ROUTE90 as the largest prospective FDA IDE trial conducted for Y90 treatment of HCC, a distinction that sets a new benchmark for clinical evidence in the radioembolization space.
Eye90 microspheres: device design and differentiation
Eye90 microspheres are a Yttrium-90 radioembolization device engineered around three capabilities not previously combined in a single Y90 platform: imageability, a streamlined delivery system, and personalized dosimetry. Dosimetry is defined as the dose targeted for the day of treatment without decay, calculated based on individual patient and tumor anatomy rather than population averages.
The imageability feature allows treating physicians to visualize microsphere distribution during and after delivery - a functional gap that clinicians have worked around for more than two decades using indirect methods. ABK Biomedical holds significant intellectual property in inorganic polymer microspheres and proprietary administration systems, and operates its own R&D and manufacturing facilities, giving the company direct control over device quality and supply.
Clinical and regulatory pathway to market
The completion of enrollment triggers the final phase of the ROUTE90 program: one year of patient follow-up before the data package is submitted in a PMA application to the FDA. The Breakthrough Device Designation already granted to Eye90 microspheres entitles ABK Biomedical to more interactive FDA review and prioritized review timelines, which could compress the period between PMA submission and a potential approval decision.
Chief Medical Officer Aravind Arepally, MD, noted that clinicians have driven Y90 outcome improvements for over 20 years despite limited device innovation. A successful PMA would make Eye90 microspheres the first imageable Y90 device available for commercial use in the United States. The device currently remains investigational and is not approved for commercial use outside authorized clinical trials.
Business impact
Interventional oncology procurement leads at hospital systems and cancer centers should begin evaluating how Eye90 microspheres would integrate into existing Y90 radioembolization workflows. The imageability and personalized dosimetry features directly affect capital equipment, procedure room configuration, and physician training budgets - decisions that require lead times of 12 to 24 months ahead of a commercial launch.
Health technology assessment teams and value-based care officers face an active 2026 planning decision: the ROUTE90 dataset, described by investigators as the highest-quality prospective study in Y90 radioembolization, will define the clinical and cost-effectiveness benchmarks that payers and hospital formulary committees use to set reimbursement positions and device access policies. Early engagement with the trial data - once published - will allow these groups to set internal coverage criteria before a PMA approval forces reactive decisions. For investor syndicates already backing ABK, the enrollment completion reduces clinical execution risk and moves the asset closer to the valuation inflection point tied to PMA submission.